Key Highlights

  • Johnson & Johnson (NYSE:JNJ) fell between 5.34% and 6% at the close on October 13, 2026 after an early decline of about 2%, making it one of the Dow's heaviest drags on the day.
  • Quarterly sales were USD 25.4 billion, up 5.9%, and full-year adjusted EPS guidance was raised to USD 11.05 to USD 11.15, according to the company release.
  • MedTech sales missed expectations, which appears to have outweighed the guidance increase and the sales beat that the company reported for the quarter. The unit sells surgical and orthopaedic devices, a key growth line for the group.
  • A talc litigation charge is reported to have cut net profit by 96%, though that figure comes from one account and has not been confirmed.

The Results and the Reaction

Johnson & Johnson (NYSE:JNJ) reported third-quarter sales of USD 25.4 billion, up 5.9%, on October 13, 2026 and lifted its full-year adjusted EPS outlook to USD 11.05 to USD 11.15. Even so, the shares fell between 5.34% and 6% at the close, after opening the day only about 2% lower. The reason offered in published accounts is that sales in the MedTech unit, which sells surgical and orthopaedic devices, missed expectations. Accounts also disagree on whether adjusted EPS beat or missed consensus, so the quality of the earnings result remains uncertain and should be confirmed against the filing. The size of the fall is unusual for a diversified healthcare group, which is why Johnson & Johnson (NYSE:JNJ) drew attention across the Dow Jones Industrial Average on a day of mixed results.

Why a Beat Can Still Sink a Stock

Large caps trade on the mix of growth, not just the total. Pharmaceuticals usually carry higher margins than devices, so a weak device line matters when investors are paying for steady growth. A litigation charge also affects reported results: when a company sets aside money for expected settlements over talc claims, the accrual reduces net income immediately even though cash goes out later. One account says the charge cut net profit by 96%, which would be a dramatic reduction, but it comes from a single account. Adjusted EPS strips such items, so the guidance raise may still reflect underlying strength. For investors, the key question is whether the talc accrual is a one-off or the start of a larger bill, and the litigation notes in the filing should clarify that point for Johnson & Johnson (NYSE:JNJ) holders.

Risks and What to Watch

The talc matter remains the major uncertainty, since settlement size and timing are hard to predict. MedTech is the other watch item, because device demand and hospital spending can swing. Investors will read management's call for evidence that the miss was timing rather than trend. The move also weighed on the Dow, which fell 0.35% on the day. UnitedHealth, the index's biggest winner, moved the other way, showing how uneven healthcare results were. The next steps are the full filing, litigation updates and the next quarterly report. Healthcare peers traded differently, with UnitedHealth rising after its own results, so sector sentiment was split. The Dow is price-weighted, so a large move in a higher-priced share is magnified in the index.

Where Things Stand

The answer is that the shares sold off on a MedTech miss and the weight of a talc charge, not on the sales total, which beat. Johnson & Johnson (NYSE:JNJ) still raised EPS guidance to USD 11.05 to USD 11.15, so the outlook is positive, but accounts differ on the adjusted EPS result. Investors should confirm figures in the filing. This is not advice. The guidance raise and the MedTech miss point in opposite directions, which explains the unusual reaction and why some observers still see the outlook as intact.